Literature DB >> 28943947

Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer.

Yu-Qian Wang1,2,3, Qiong-Jie Zhi1,2,3, Xin-Yue Wang1,2,3, Dong-Sheng Yue1,2,4, Kai Li1,2,3, Ri-Cheng Jiang1,2,3.   

Abstract

The aim of the present study was to investigate the prognostic value of the combined platelet (PLT), fibrinogen (FBG), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) (CO-NPF) for postoperative outcomes in patients with lung adenosquamous cancer (ASC). Test results from patients who presented at The Cancer Institute and Hospital of Tianjin Medical University between January 2005 and December 2013 were retrospectively reviewed. CO-NPF was scored between 0 and 4 according to increased PLT, FBG, NLR and PLR prior to being split into two groups based on the presence (≥2) or absence (<2) of the combination of increased inflammatory indexes. In total, data from 134 patients with ASC were reviewed for the present study. Multivariate analysis identified that increased CO-NPF (P=0.001 and P<0.001, respectively), PLR (P=0.011 and P=0.001, respectively) and FBG (P=0.001 and P<0.001, respectively) were independently associated with shorter disease-free survival (DFS) and overall survival (OS). NLR (P=0.006) and PLT (P=0.001) were independent prognostic factors for OS. The area under the receiver operating characteristic curves of CO-NPF (area under the curve, 0.652, P=0.008, 95% confidence interval, 0.551-0.752) was increased compared with NLR, PLR, PLT and FBG individually, suggesting that CO-NPF has greater predictive value. CO-NPF was significantly and independently associated with shorter DFS and OS, and had greater predictive value compared with NLR, PLR, PLT and FBG in patients with ASC who underwent surgery.

Entities:  

Keywords:  fibrinogen; lung adenosquamous cancer; neutrophil to lymphocyte ratio; platelet; platelet to lymphocyte ratio

Year:  2017        PMID: 28943947      PMCID: PMC5594242          DOI: 10.3892/ol.2017.6660

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Adenosquamous carcinoma of the lung. Clinicopathologic and immunohistochemical features.

Authors:  T Ishida; S Kaneko; H Yokoyama; T Inoue; K Sugio; K Sugimachi
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

Review 2.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

3.  Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer.

Authors:  He-Guo Jiang; Jian Li; Shun-Bing Shi; Ping Chen; Li-Ping Ge; Qian Jiang; Xin-Ping Tang
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

Review 4.  Expression of thrombospondin-1 in cancer: a role in tumor progression.

Authors:  X Qian; G P Tuszynski
Journal:  Proc Soc Exp Biol Med       Date:  1996-07

5.  Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer.

Authors:  Liming Sheng; Min Luo; Xiaojiang Sun; Nengming Lin; Weimin Mao; Dan Su
Journal:  Int J Cancer       Date:  2013-06-14       Impact factor: 7.396

6.  The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

Authors:  Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

7.  Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases.

Authors:  P L Fitzgibbons; W H Kern
Journal:  Hum Pathol       Date:  1985-05       Impact factor: 3.466

8.  Adenosquamous carcinoma of the lung: CT, FDG PET, and clinicopathologic findings.

Authors:  Youkyung Lee; Jin-Haeng Chung; Sang Eun Kim; Tae Jung Kim; Kyung Won Lee
Journal:  Clin Nucl Med       Date:  2014-02       Impact factor: 7.794

9.  MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival.

Authors:  Kun Y Kwon; Jae Y Ro; Nicholas Singhal; Deanna E Killen; Anna Sienko; Timothy C Allen; Dani S Zander; Roberto Barrios; Abida Haque; Philip T Cagle
Journal:  Arch Pathol Lab Med       Date:  2007-04       Impact factor: 5.534

10.  Platelet count predicts prognosis in operable non-small cell lung cancer.

Authors:  Dangfan Yu; Bingjiang Liu; Lizhen Zhang; Kaiqi DU
Journal:  Exp Ther Med       Date:  2013-03-12       Impact factor: 2.447

View more
  14 in total

1.  The association between plasma fibrinogen levels and lung cancer: a meta-analysis.

Authors:  Ke Zhang; Ye Xu; Shanyue Tan; Xueyan Wang; Mulong Du; Lingxiang Liu
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

2.  The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma

Authors:  Oktay Halit Aktepe; Gürkan Güner; Deniz Can Güven; Taha Koray Şahin; Fadime Sinem Ardıç; Deniz Yüce; Şuayib Yalçın; Mustafa Erman
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

Review 3.  Research progress of the clinicopathologic features of lung adenosquamous carcinoma.

Authors:  Jing Wang; Yanling Wang; Mengting Tong; Hongming Pan; Da Li
Journal:  Onco Targets Ther       Date:  2018-10-16       Impact factor: 4.147

4.  [Prognostic Value of Neutrophil-to-lymphocyte Ratio in Patients 
with Lung Adenocarcinoma Treated with Radical Dissection].

Authors:  Gaoxiang Wang; Ran Xiong; Hanran Wu; Guangwen Xu; Caiwei Li; Xiaohui Sun; Mingran Xie
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-08-20

5.  Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis.

Authors:  Hai Zhong; Yingying Qian; Surong Fang; Ying Wang; Yun Tang; Wei Gu
Journal:  J Cancer       Date:  2018-10-10       Impact factor: 4.207

6.  Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: interaction effect with disease severity-a retrospective study.

Authors:  Yanfei Shen; Xinmei Huang; Weimin Zhang
Journal:  BMJ Open       Date:  2019-01-25       Impact factor: 2.692

7.  Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis.

Authors:  Yuan Yuan; Hai Zhong; Liang Ye; Qian Li; Surong Fang; Wei Gu; Yingying Qian
Journal:  BMC Pulm Med       Date:  2020-04-20       Impact factor: 3.317

8.  Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer.

Authors:  Yi Zhang; Junyan Cao; Yinan Deng; Yiming Huang; Rong Li; Guozhen Lin; Min Dong; Zenan Huang
Journal:  Clinics (Sao Paulo)       Date:  2020-02-27       Impact factor: 2.365

9.  Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  PLoS One       Date:  2018-07-13       Impact factor: 3.240

10.  Predictive value of neutrophil to lymphocyte and platelet to lymphocyte ratio in COVID-19.

Authors:  Shiping Zhu; Lei Dong; Wanru Cai
Journal:  Crit Care       Date:  2020-08-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.